$12M Vioxx Deal Requires Merck To Add Safety Checks

Law360, New York (February 10, 2010, 3:07 PM EST) -- A New Jersey state judge has preliminarily approved a settlement of a Vioxx-related shareholder derivative action that will see Merck & Co. Inc. institute stronger drug-safety measures, appoint a chief medical officer and pay nearly $12.2 million in attorneys' fees.

An unnamed judge of the Superior Court of New Jersey, Atlantic County Division, gave a preliminary sign-off on the settlement Monday, according to a filing with the U.S. Securities and Exchange Commission. If the deal gets final approval, all shareholder derivative litigation stemming from the discontinued...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.